LNSR LENSAR, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.67

Period return

-4.60 (-44.79%)

Volume

42.8K

2026-06-01O $5.79 H $5.95 L $5.62 C $5.67MA5 $5.88MA20 $5.74MA60 $6.39MA120 $9.17

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 03. 18.MediumBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2025. 03. 25.MediumHOLDlast year
Lake Street: Hold
US analyst rating / recommendation change.
2025. 03. 01.LowBUYlast year
Lake Street: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $8.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Sector: Healthcare
Industry: Medical Devices
HQ: Orlando, FL, United States
Fiscal year end: —
Employees: 150
IPO date: —

View details →

2024. 03. 20.MediumBUY2 years ago

Lake Street: Buy

US analyst rating / recommendation change.

2021. 11. 22.MediumBUY5 years ago

BTIG: Buy

US analyst rating / recommendation change.

2021. 02. 24.MediumBUY5 years ago

SVB Leerink: Outperform

US analyst rating / recommendation change.

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.27	—	—	$14.65M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-2.32	—	—	$12.28M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-1.11	—	—	$31.14M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.98	—	—	$19.33M	Reported

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 03. 18.	BTIG	—	Upgrade	Neutral → Buy	—	BTIG: Neutral → Buy
2025. 03. 25.	Lake Street	—	Downgrade	Buy → Hold	—	Lake Street: Buy → Hold

Available on Pro+

See full research history

Compare a firm's past rating changes and its actions on other stocks in the same sector.

View plans

Key stats

As of FY2026Q1 · Source: SEC/DART + price data

Market cap$70.21M

Shares out.12M

PER—

EPS (TTM)-$4.60

PBR14.44x

BPS$0.40

Dividend/share—

Dividend yield—

Consensus—

Price target$8.50+46.6%

Target range$7.00 ~ $10.00· 2 analysts

Available on Premium+

See the key changes, summarized by AI

Filings, earnings, and institutional changes summarized in one paragraph, with source links.

View plans

No holdings data to show.

Available on Pro+

See all institutional holding changes

See new positions, full exits, and weight changes.

View plans